Jacks Tyler 4
Research Summary
AI-generated summary
AMGEN Director Tyler Jacks Receives 665 RSUs
What Happened
Tyler Jacks, a director of Amgen Inc. (AMGN), was awarded 665 restricted stock units (RSUs) on May 19, 2026. The RSUs show an acquisition price of $0.00 (total reported cash consideration $0) and, per the filing, vested immediately. Vested RSUs are paid in shares on a one-to-one basis and may be deferred by the director according to an elected deferral schedule.
Key Details
- Transaction date: 2026-05-19; Form 4 filed: 2026-05-21 (appears timely within the 2-business-day Form 4 window).
- Transaction type/code: Award/Grant (A).
- Amount: 665 RSUs acquired at $0.00 (reported value $0).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote F1: RSUs granted under Amgen’s 2009 Director Incentive Program and vested immediately; vested RSUs are settled one-for-one in common stock and may be deferred.
- Footnote F2: The filing also references 2,975 dividend equivalents (DEs) credited to unvested RSUs; DEs are paid out in shares per the vesting schedule (plus cash for any fractional share).
Context
This was a compensation award to a director, not an open-market purchase or sale. Awards and vested RSUs represent company compensation and do not directly signal a director’s buying or selling intent in the public market. Dividend equivalents noted in the footnotes are additional credits tied to unvested RSUs and will convert to shares according to vesting terms.